Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telithromycin vs cefuroxime axetil for acute otitis media in children
2004-000738-34Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Feb 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telithromycin in acute otitis media (AOM) (2 arms), sponsored by Sanofi. Primary endpoint: Primary clinical efficacy at posttherapy/test-of-cure (TOC) visit. Started Feb 2005; status: terminated.
02
Drugs
telithromycin
03
Conditions
acute otitis media (AOM)
Beyond the preview
Go deeper on 2004-000738-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000738-34.